Lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer

• Published in: Expert review of anticancer therapy Vol. 22; no. 11; pp. 1163 - 1175
• Main Authors: Shah, Hina, Ravi, Praful, Sonpavde, Guru, Jacene, Heather
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 02-11-2022
• Subjects: Clinical Trials, Phase II as Topic; Dipeptides - adverse effects; Humans; Lu-vipivotide tetraxetan; Lutetium - adverse effects; Lutetium-177; Male; prostate cancer; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant - drug therapy; Prostatic Neoplasms, Castration-Resistant - pathology; PSMA-617; Radiopharmaceuticals - pharmacology; Randomized Controlled Trials as Topic; Taxoids - therapeutic use; Treatment Outcome; 177Lu-vipivotide tetraxetan; prostate cancer; Lutetium-177; PSMA-617
• ISSN: 1473-7140; 1744-8328
• DOI: 10.1080/14737140.2022.2139679

177
Lu-vipivotide tetraxetan is a radiopharmaceutical that selectively targets prostate-specific membrane antigen (PSMA) and delivers beta-radiations to kill prostate cancer cells.
Extensive experience outside the United States as well as randomized phase II and phase III data demonstrate that
177
Lu-vipivotide tetraxetan is a safe, generally well tolerated, and effective therapy for men with mCRPC.
177
Lu-vipivotide tetraxetan was approved by the FDA in March 2022 for the treatment of PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) after androgen receptor pathway inhibition and taxane-based chemotherapy based on the results of the VISION trial.
This review discusses the development and studies leading to the approval of
177
Lu-vipivotide tetraxetan. In all,
177
Lu-vipivotide tetraxetan is an exciting new tool in the arsenal for men with mCRPC after novel androgen pathway inhibitors and at least one taxane chemotherapy. Optimal selection of patients, sequencing of
177
Lu-vipivotide tetraxetan with the other agents available to treat mCRPC, and the use of dosimetry are current areas of interest with great potential and opportunities for further individual patient optimization using the tools of theranostics.